Strong Overall Performance
Delivered CHF 3.6 billion in sales with a 19% CER sales growth compared to 2024, resulting in a core EBITDA of CHF 1.1 billion and a margin growth to 29.6%.
CDMO Business Growth
Excluding CHI, CDMO business saw a 23.1% sales growth leading to a core EBITDA margin slightly above 30%.
Upgraded CDMO Outlook
Raised guidance to 20% to 21% CER sales growth and a core EBITDA margin of 30% to 31% for full year 2025.
Integrated Biologics Success
Reported strong CER sales growth of almost 40%, supported by Vacaville acquisition and high demand for assets.
Advanced Synthesis Improvement
Strong CER sales growth of above 18% with a core EBITDA margin of 40.3%, an increase of 6.9 percentage points versus H1 2024.
Capsules and Health Ingredients Recovery
Flat sales growth versus H1 2024 and a core EBITDA margin increase to 26.2%.